Fibrin

Medical Adhesives & Sealants World Market Report 2024: Remineralizing Agents Being Used to Restore Resin-Based Dental Materials - ResearchAndMarkets.com

Retrieved on: 
월요일, 4월 22, 2024
Medical Supplies, Health, Internal, Acrylic, Catheter, Polyurethane, Instrument, Metal, Dental, Fibrin, Cosmetics, Skin, Dentistry, USB On-The-Go, Medical device, Polymer, Suture, Plastic surgery, Adhesive, Surgical instrument, Equipment

The "Medical Adhesives & Sealants World Market Report" has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Adhesives & Sealants World Market Report" has been added to ResearchAndMarkets.com's offering.
  • There are several applications for adhesives and sealants the medical sector, including in the areas of dentistry & cosmetics, internal & external surgery and medical devices & equipment.
  • Among these, acrylic, silicone, polyurethane, polyethylene glycol and cyanoacrylate are most widely used materials to make synthetic/semi-synthetic adhesives & sealants.
  • This world market compendium analyzes the market for Medical Adhesives & Sealants at a high level by resin type/sub-type, application, end-use sector and geographic region.

A New Therapeutic Target for Traumatic Brain Injury

Retrieved on: 
금요일, 4월 19, 2024
Alzheimer's disease, Brain, Inflammation, Coagulation, Mutation, Traffic barrier, Bleeding, Mouse, Skull, Explosion, Gladstone Institutes, Fibrin, Blood, Impulsivity, Research, Accident, Trauma, Doctor of Philosophy, Depression, Life, Brain damage, Head injury, Injury, Patient, DSM-IV codes, Multiple sclerosis, Neurology, Neuron, Traumatic brain injury, Immune system, Journal, Frasier, SAN, Disability, Vaccine

SAN FRANCISCO, April 19, 2024 /PRNewswire/ -- For the roughly 1.5 million Americans per year who survive a traumatic brain injury, health outcomes vary widely. Not only can these injuries lead to a loss of coordination, depression, impulsivity, and difficulty concentrating, but they come with an amplified risk for developing dementia in the future.

Key Points: 
  • SAN FRANCISCO, April 19, 2024 /PRNewswire/ -- For the roughly 1.5 million Americans per year who survive a traumatic brain injury, health outcomes vary widely.
  • "We knew that a specific blood protein, fibrin, was present in the brain after traumatic brain injury, but we didn't know until now that it plays a causative role in brain damage after injury," says Ryu, who led the study that appears in the Journal of Neuroinflammation.
  • But in this case, the traumatic brain injury itself causes the blood to leak into the brain.
  • They also produced three-dimensional imaging of a whole intact mouse brain, showing blood-brain barrier leaks and abundant fibrin in traumatic brain injury.

Cresilon Announces Distribution Partnerships for VETIGEL with Leading Animal Health and Veterinary Product Suppliers

Retrieved on: 
금요일, 4월 19, 2024
Neoplasm, Anesthesia, Bleeding, Patient, Fibrin, Dentistry

NEW YORK, April 19, 2024 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into distribution agreements for its revolutionary hemostatic gel, VETIGEL®, to be sold directly to veterinary surgeons through several of the leading animal health and veterinary product suppliers in the U.S., including Covetrus, MWI Animal Health, and Patterson Veterinary Supply.

Key Points: 
  • Revolutionary hemostatic gel for veterinary surgeons now available through Covetrus, MWI Animal Health, and Patterson Veterinary Supply
    NEW YORK, April 19, 2024 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into distribution agreements for its revolutionary hemostatic gel, VETIGEL®, to be sold directly to veterinary surgeons through several of the leading animal health and veterinary product suppliers in the U.S., including Covetrus, MWI Animal Health, and Patterson Veterinary Supply.
  • A plant-based hemostatic gel that instantly stops and controls bleeding without the need to apply manual pressure, VETIGEL is now available online for U.S. veterinary surgeons through Covetrus , MWI Animal Health , and Patterson Veterinary Supply .
  • "We are excited to partner with many of the leading animal health companies to help more veterinary surgeons easily access a groundbreaking all-natural hemostatic product that reduces blood loss and anesthesia time, resulting in better patient outcomes," said Matt Lewis, Vice President of Sales at Cresilon.
  • VETIGEL offers veterinary surgeons a safe and effective way to rapidly stop and control bleeding across a wide range of surgical procedures and medical emergencies.

Global Medical Adhesives & Sealants Market Report 2024 - Wide Array of Solutions and Application Areas Offered by Soft-Skin Adhesives Facilitating Market Growth - ResearchAndMarkets.com

Retrieved on: 
월요일, 4월 1, 2024
Medical Supplies, Health, Blood pressure, Adhesive, Dentistry, Growth, Prevalence, Vital signs, Patient, Conditional sentence, Radiation, Palliative care, Metal, Bacteria, Instrument, Electrode, Fibrin, Chronic radiation syndrome, Skin, Collagen, EKG, USB On-The-Go, Cosmetics, Acrylic

The "Global Medical Adhesives & Sealants Market - Resin Types, Applications and End-use Sectors" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Medical Adhesives & Sealants Market - Resin Types, Applications and End-use Sectors" report has been added to ResearchAndMarkets.com's offering.
  • The growth in demand for soft-skin adhesives has been made possible by the wide variety of their applications in the medical, pharmaceutical and personal care areas.
  • Soft-skin adhesives find application in a range of medical areas, which comprise skin therapies, wound dressing and wearable medical devices, providing further impetus to demand for them.
  • The range of applications for adhesives and sealants the medical sector includes the areas of dentistry & cosmetics, internal & external surgery and medical devices & equipment.

Grifols announces positive topline phase 3 fibrinogen clinical trial results

Retrieved on: 
수요일, 2월 14, 2024
Acquisition, Liver, Bleeding, MCE, USD, SCAP, Immunoglobulin M, FC, Fibrinogen, Wound healing, Standard of care, Fibrin, Risk, Safety, Immunoglobulin G, Element, GRFS, Medicine, Patient, Immunoglobulin A, AFD, Clinical trial, Protein, GRF, Plasma, Factor, CAP, Community-acquired pneumonia, Pharmaceutical industry

AFD, which typically occurs during surgical procedures when there’s insufficient fibrinogen to arrest bleeding, is commonly treated with cryoprecipitate (a plasma extract) or fresh frozen plasma, both containing fibrinogen.

Key Points: 
  • AFD, which typically occurs during surgical procedures when there’s insufficient fibrinogen to arrest bleeding, is commonly treated with cryoprecipitate (a plasma extract) or fresh frozen plasma, both containing fibrinogen.
  • Fibrinogen, a plasma protein produced in the liver, plays a key role in stopping blood loss and in wound healing.
  • “The positive results for Biotest’s fibrinogen are an important milestone and strengthen a Grifols innovation strategy that’s diversified across plasma and non-plasma, balanced between internal and external investments, and includes both shorter- and longer-term development cycles,” said Victor Grifols Deu, Grifols Chief Operating Officer.
  • The acquisition of Biotest has significantly reinforced Grifols’ access to plasma, as well as the company’s pipeline and sales presence.

Ethicon Introduces ETHIZIA™ Hemostatic Sealing Patch, Clinically Proven to Stop Disruptive Bleeding

Retrieved on: 
수요일, 11월 15, 2023
Acquisition, Surgeon, Clinical trial, Patient, CE marking, GATT, Hemostasis, LATAM, Fibrin, Ethicon

RARITAN, N.J., Nov. 15, 2023 /PRNewswire/ -- Ethicon*, a Johnson & Johnson MedTech company**, today announced the approval of ETHIZIA™, an adjunctive hemostat solution which has been clinically proven to achieve sustained hemostasis in difficult to control bleeding situations.1 Comprised of unique synthetic polymer technology, ETHIZIA™ Hemostatic Sealing Patch is the first and only hemostatic matrix designed to be equally active and efficacious on both sides***.2 Designed for maximum adaptability, it can be stuffed, rolled, pulled apart, trimmed and tailored,3, 4 making it easy to handle in both open and minimally invasive surgeries.5 In 80% of clinical trial patients studied****, ETHIZIA™ Hemostatic Sealing Patch stopped bleeding in 30 seconds, an average of six times faster than the leading Fibrin Sealant Patch*****.6 7

Key Points: 
  • "As a global leader in surgery, we are committed to empowering healthcare providers to safeguard patients from surgical complications by continuously delivering breakthrough solutions," said Vladimir Makatsaria, Company Group Chairman, Ethicon.
  • "Disruptive bleeding can contribute to serious complications, and with the addition of ETHIZIA™ to our portfolio, we are well positioned to deliver critical hemostasis solutions for patients."
  • In May 2022, Ethicon acquired GATT Technologies B.V., a Netherlands-based company using differentiated synthetic polymer to create hemostatic and sealant products to address complex surgical bleeding and leak challenges.
  • As a global leader in surgery, Ethicon harnesses deep expertise to design surgical solutions that are smarter, less invasive, and more personalized.

Iteld Plastic Surgery Launches New Aesthetics Website

Retrieved on: 
화요일, 10월 31, 2023
Fibrin, Patient, Ageing, Plasma, Platelet-rich fibrin, Exosome, Skin, Protein, Elastin, PRF, Collagen, Regeneration, Platelet-rich plasma, Blood, PRP, Serum albumin, Dentistry, Blood product, Cosmetics

The Iteld Aesthetics Institute site, which launched this summer, includes detailed information on services such as PRP and PRF , PRF EZ Gel plasma filler, Sculptra® biostimulatory fillers , and microneedling with exosomes.

Key Points: 
  • The Iteld Aesthetics Institute site, which launched this summer, includes detailed information on services such as PRP and PRF , PRF EZ Gel plasma filler, Sculptra® biostimulatory fillers , and microneedling with exosomes.
  • Patients who are seeking other types of surgical and non-surgical cosmetic procedures can find more details on various options on the main Iteld Plastic Surgery website.
  • For more information on natural non-surgical skin rejuvenation treatments, contact Chicago’s Iteld Plastic Surgery.
  • Call (312) 757-4505, fill out a contact form to schedule a consultation, or visit the Iteld Aesthetics Institute site for more details.

Therini Bio Announces Interim Results from the Phase 1 Trial of THN391 for the Potential Treatment of Dementia

Retrieved on: 
화요일, 10월 24, 2023
Fibrin, Ageing, Half-life, Cmax, Publication, Treatment, Boston Park Plaza, MAD, SAD, Dementia, Poster, Safety, Retina, Vaccine

SACRAMENTO, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Therini Bio, Inc., a biotech company focused on developing fibrin targeted therapies to treat inflammatory neurodegenerative and retinal diseases, today announced interim results from the Phase 1 trial of its lead candidate, THN391, for the treatment of dementia. The data will be detailed in a poster presentation at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) conference taking place from October 25-27, 2023, in Boston, MA.

Key Points: 
  • SACRAMENTO, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Therini Bio, Inc., a biotech company focused on developing fibrin targeted therapies to treat inflammatory neurodegenerative and retinal diseases, today announced interim results from the Phase 1 trial of its lead candidate, THN391, for the treatment of dementia.
  • Vascular dysfunction is a key driver in many neurodegenerative diseases, with fibrin playing a major role.
  • THN391 is a potential first-in-class, therapeutic, monoclonal antibody that is designed to target the inflammatory properties of fibrin without disrupting coagulation and protective innate immunity.
  • Data from the first two cohorts, 0.3 mg/kg and 1.0 mg/kg, demonstrated a half-life of approximately 50 days in both groups.

Cresilon Announces Distribution Agreement for VETIGEL with Penn Veterinary Supply

Retrieved on: 
화요일, 8월 22, 2023
Partnership, Bleeding, Veterinarian, Animal Health, Marketing, Animal, Standard of care, Patient, Fibrin, Pet, Neoplasm, Veterinary medicine

NEW YORK, Aug. 22, 2023 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary hemostatic gel, VETIGEL®, to be sold directly to veterinarians through Penn Veterinary Supply, an independent U.S. regional distributor of veterinary products and services.

Key Points: 
  • NEW YORK, Aug. 22, 2023 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary hemostatic gel, VETIGEL®, to be sold directly to veterinarians through Penn Veterinary Supply, an independent U.S. regional distributor of veterinary products and services.
  • VETIGEL is now available for veterinarians through Penn Veterinary Supply.
  • Cresilon's VETIGEL – a plant-based hemostatic gel that instantly stops and controls bleeding without the need to apply manual pressure – is now available for veterinarians through Penn Veterinary Supply .
  • Laura Williams, Penn Veterinary Supply, Director of Sales and Marketing commented; "Penn Veterinary Supply is excited to add VETIGEL to our portfolio of hemostatic technologies.

RedDress Receives Vizient Contract for Advanced Wound Care Solution ActiGraft PRO

Retrieved on: 
화요일, 8월 22, 2023
Diabetes, Human, The Queen's Award for Enterprise: Innovation (Technology) (2008), Mouth ulcer, Plasma, TEL, Patient, Fibrin, Patient safety, FDA, Safety, Wound healing, Hospital, Health insurance, Vizient, Inc., Medicare

TEL AVIV, Israel and JACKSONVILLE, Fla., Aug. 22, 2023 /PRNewswire/ -- RedDress, developers of the ActiGraft PRO system, a personalized and autologous wound care solution created from patients' own whole blood, today announced that its ActiGraft PRO product is now available through Vizient, the nation's largest provider-driven healthcare performance improvement company. RedDress secured an Innovative Technology contract with Vizient in October 2022 and G-Code reimbursement status from Medicare and Medicare Advantage in July 2023.

Key Points: 
  • Medicare and Medicare Advantage reimbursement status was recently obtained for ActiGraft PRO, enabling the wound care industry's most advanced whole-blood wound care solution to be purchased by wound care centers and practitioners nationally
    TEL AVIV, Israel and JACKSONVILLE, Fla., Aug. 22, 2023 /PRNewswire/ -- RedDress , developers of the ActiGraft PRO system, a personalized and autologous wound care solution created from patients' own whole blood, today announced that its ActiGraft PRO product is now available through Vizient, the nation's largest provider-driven healthcare performance improvement company.
  • "We are excited for the momentum we are experiencing since obtaining Medicare reimbursement status and are thrilled to make ActiGraft PRO now available to wound care specialists nationally through Vizient," said Alon Kushnir, CEO and Co-Founder of RedDress.
  • "Autologous, blood-based therapies are the future of wound care, and with ActiGraft PRO as the leading solution in the category, our contract with Vizient will significantly increase access to advanced wound care for patients and healthcare providers."
  • The ActiGraft PRO system is an autologous, point-of-care wound management solution created from patient's whole blood.